Sector
PharmaceuticalsOpen
₹4,845Prev. Close
₹4,822Turnover(Lac.)
₹4,594.92Day's High
₹4,898.9Day's Low
₹4,824.352 Week's High
₹6,439.952 Week's Low
₹4,491.65Book Value
₹1,073.52Face Value
₹2Mkt Cap (₹ Cr.)
58,423.05P/E
27.95EPS
174.78Divi. Yield
0.9229 May 2024
12:00 AM
AGM
Announcement Date: 29 May, 2024
16 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 23.91 | 23.91 | 23.91 | 23.91 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 10,530.7 | 9,325.94 | 8,719.75 | 7,601.84 |
Net Worth | 10,554.61 | 9,349.85 | 8,743.66 | 7,625.75 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 8,829.81 | 7,219.68 | 6,677.08 | 5,300.26 |
yoy growth (%) | 22.3 | 8.12 | 25.97 | 16.53 |
Raw materials | -3,565.89 | -2,665.02 | -2,550.56 | -2,075.22 |
As % of sales | 40.38 | 36.91 | 38.19 | 39.15 |
Employee costs | -1,434.49 | -1,158.72 | -1,066.76 | -861.63 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,753.37 | 1,897.08 | 1,338.08 | 934.29 |
Depreciation | -218.98 | -198.93 | -186.84 | -107.65 |
Tax paid | -212.12 | -199.22 | -73.66 | -218.45 |
Working capital | 954.38 | 1,212.29 | 1,245.84 | 514.21 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.3 | 8.12 | 25.97 | 16.53 |
Op profit growth | -7.11 | 32.79 | 47.85 | 13.05 |
EBIT growth | -7.66 | 40.9 | 42.42 | 5.28 |
Net profit growth | -8.53 | 33.26 | 76.63 | -18.94 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 12,964.52 | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 12,964.52 | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 493.74 | 310.84 | 216.08 | 162.65 | 233.21 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,679.7 | 94.05 | 4,02,788.36 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,876 | 82.52 | 1,82,282.67 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,508.7 | 25.32 | 1,21,846.76 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,334.1 | 59.26 | 1,12,908.79 | 474 | 0.96 | 2,385 | 224.33 |
Dr Reddys Laboratories Ltd DRREDDY | 1,291.3 | 20.06 | 1,07,932.29 | 1,200.7 | 0.62 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Basudeo N Singh
Managing Director
SANDEEP SINGH
Executive Director
Mritunjay Kumar Singh
Non-Exec. & Independent Dir.
A K Purwar
Non-Exec. & Independent Dir.
SANGEETA KAPILJIT SINGH
Non-Exec. & Independent Dir.
SUDHA RAVI
Company Sec. & Compli. Officer
Manish Narang
Non-Exec. & Independent Dir.
Narendra Aneja
Executive Director
SARVESH SINGH
Executive Director
Madhurima Singh
Independent Director
Sujjain Talwar
Executive Director
Srinivas Singh
Alkem House SenapatiBapat Marg,
Lower Parel,
Maharashtra - 400013
Tel: 91-22-39829999
Website: http://www.alkemlabs.com
Email: investors@alkem.com ; contact@alkem.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The company is engaged in the development, manufacture and sale of pharmac...
Read More
Reports by Alkem Laboratories Ltd
What is the Alkem Laboratories Ltd share price today?
What is the Market Cap of Alkem Laboratories Ltd?
What is the PE and PB ratio of Alkem Laboratories Ltd?
What is the 52 Week High and Low of Alkem Laboratories Ltd?
What is the CAGR of Alkem Laboratories Ltd?
What is the shareholding pattern of Alkem Laboratories Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
